Author: admin
A new MRM Health R&D partnership in immunotherapy points to broader clinical and investment upside. Belgian microbiome company MRM Health has taken another step toward broadening the clinical and commercial case for microbiome-based therapeutics, announcing a new R&D collaboration in cancer immunotherapy just months after closing a €55m (US$64m) Series B financing round. The Ghent-based biotech revealed it has entered into a strategic partnership with the research group of Professor Emile Voest, Senior Group Leader at the Netherlands Cancer Institute (NKI) and Senior Investigator at the Oncode Institute. While the immediate focus is on improving cancer immunotherapy, the collaboration underscores…
Credit: CIPhotos / iStock / Getty Images Plus Cancer immunotherapy has reshaped modern oncology, delivering long-lasting remissions in diseases such as melanoma, lung cancer, and certain blood cancers. Yet for many patients, these therapies fall short. Tumors may initially respond but later rebound, or they may resist immune attack from the outset. A new study, published in Cell Reports, sheds light on why this happens—and suggests a promising way to tip the balance back in favor of the immune system. Scientists from the Olivia Newton-John Cancer Research Institute, in collaboration with the Walter and Eliza Hall Institute of Medical Research and La Trobe University,…
Before a newly synthesized protein can undergo folding, it must be processed and transported to the correct location within the cell after emerging from the ribosome. N-terminal acetylation (Nt-acetylation) is a ubiquitous irreversible modification that affects a variety of protein properties and functions including folding, aggregation propensity, half-life, localization, and assembly. While modifications on histones influence chromatin function, how they occur co-translationally on these abundant and small proteins is not understood. In a new study published in Science Advances titled, “Mechanism of cotranslational modification of histones H2A and H4 by MetAP1 and NatD,” researchers from ETH Zürich have uncovered how histones H4 and H2A…
The most read stories in cell biology range from metabolism to the future of biomedical research models.Image credit:©iStock.com, spawnsThis past year, we explored a lot of new cell biology research—from cancer to plants to microbes, and more! It’s hard to believe what can fit in a year. Yet as we say goodbye to 2025, we want to take a moment to look back on some of our most popular stories in cell biology. Make sure you catch these stories before we break new ground in 2026.Cysteine depletion converted white adipocytes into heat-generating brown adipocytes in mice.Dixit laboratory, Yale School of…
Credit: Gilnature/Getty Images Immune therapies that have used regulatory T cells (Tregs) have long been limited by difficulties in suppressing the harmful immune response in autoimmune disorders without compromising the immune system as a whole. While Tregs are the natural mechanism for maintaining immune tolerance, inducing antigen-specific Tregs safely and efficiently in patients has been difficult. Existing strategies often depend on broad immunosuppression or complex cell therapies, both of which carry risks such as infections, malignancies, or non-specific immune suppression. Now, researchers at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University have developed a…
Startup targets ‘brainspan’ with EEG-powered headphones designed to make monitoring cognitive health as normal as heart rate. Consumer neurotech company Neurable has secured $35 million in Series A financing to advance its wearable EEG technology designed to support brain health. The Boston-based firm claims its non-invasive approach can make brain health a component of everyday health tracking, alongside well-established metrics such as sleep, activity, and heart rate. “Our mission is to make understanding your brain as natural and intuitive as checking your steps,” said Neurable CEO Dr Ramses Alcaide. The new funding, which brings the total raised by Neurable to…
A high-fat diet is one of the biggest risk factors for developing liver cancer. Now, a new study reveals a potential mechanism underlying this. The team found that, in response to a high-fat diet, mature hepatocytes in the liver revert to an immature, stem-cell-like state. Although this helps the cells survive the stressful conditions created by the high-fat diet, it makes them more likely to become cancerous in the long term. “If cells are forced to deal with a stressor, such as a high-fat diet, over and over again, they will do things that will help them survive, but at…
Credit: Mohammed Haneefa Nizamudeen / Getty Images A pilot six-month community outreach program in Osun State, Nigeria helped boost local knowledge about colorectal cancer and detection of early stage cancer and precancerous polyps. As reported in the journal Cancer, the international research team found that awareness of colorectal cancer in the local area increased from 16.8% before the campaign to 96.9% afterwards. The campaign directed 116 people to have a colonoscopy and picked up stage 0 colorectal cancer in two patients and advanced adenomas in 11, allowing early treatment to take place. “According to the 2022 GLOBOCAN report, colorectal cancer…
Devin Partida on the fine line between longevity wellness and regulated healthcare – and why product design decisions matter early. The longevity sector has exploded in recent years, channeling big science and hot funding into services that promise to extend healthy life. However, when startups start offering diagnostics, personalized recommendations or treatment-like interventions, the line between wellness and regulated healthcare can quickly blur. Crossing that line can trigger licensing, clinical trial, privacy and liability obligations that change a business overnight. The real question for founders is where that dividing line lies and how to design products and processes that deliver…
View eBook The oligonucleotide therapeutics market is growing, and the pipeline is diverse. With more than 1200 oligo therapeutics in development and over 20 commercialized oligonucleotide drugs on the market to date, the potential for these highly specific sequences is being realized and is set to continue. Building on 40 years of experience, we at Cytiva understand that achieving high-quality and cost-effective oligonucleotides for your patients depends on successful drug development, optimization to manufacture, and a smooth scale-up. Having expertise and experience at hand is key when optimizing your synthesis process and will provide the right support for your full…